PhotoCure's Metvix: Creating a New Market
Executive Summary
Norway's PhotoCure is one of the few European biotech companies with a marketed product. Skin cancer photodynamic therapy Metvix PDT has already been launched in Scandinavia, and more recently by partner Galderma in Germany and the UK. Other PDT firms have struggled to educate physicians to accept a new kind of treatment-and thereby recoup the costs attached. PhotoCure is hoping that Metvix's improved efficacy and cosmetic advantages will help it create a market for PDT products.
You may also be interested in...
Photobiotics Ltd.
Imperial College spin-out Photobiotics reckons it's on track towards making photodynamic therapy (PDT) more targeted, as well as addressing some of the technique's other weaknesses.
Pandemic Spotlights Tensions Between Profit And Philanthropy
The COVID-19 pandemic has triggered extraordinary levels of collaboration. But competition remains, and many newly created coalitions have yet to be stress tested.
Virtual Health Care: Where Does This Leave Pharma Marketing?
COVID-19 has triggered a dramatic shift toward virtual consultations and telemedicine, encouraged by more relaxed regulations and payer support.
Need a specific report? 1000+ reports available
Buy Reports